New Edge Advisors, LLC Madrigal Pharmaceuticals, Inc. Transaction History
New Edge Advisors, LLC
- $15 Billion
- Q3 2024
A detailed history of New Edge Advisors, LLC transactions in Madrigal Pharmaceuticals, Inc. stock. As of the latest transaction made, New Edge Advisors, LLC holds 70 shares of MDGL stock, worth $23,436. This represents 0.0% of its overall portfolio holdings.
Number of Shares
70
Previous 70
-0.0%
Holding current value
$23,436
Previous $19,000
26.32%
% of portfolio
0.0%
Previous 0.0%
Shares
8 transactions
Others Institutions Holding MDGL
# of Institutions
296Shares Held
21.9MCall Options Held
819KPut Options Held
644K-
Janus Henderson Group PLC London, X02.48MShares$830 Million0.28% of portfolio
-
John Paulson Paulson & Co. Inc. | New York, Ny2.04MShares$684 Million29.57% of portfolio
-
Avoro Capital Advisors LLC New York, NY2.03MShares$679 Million6.48% of portfolio
-
Rtw Investments, LP New York, NY1.99MShares$667 Million6.74% of portfolio
-
Baker Bros. Advisors LP New York, NY1.97MShares$661 Million4.49% of portfolio
About MADRIGAL PHARMACEUTICALS, INC.
- Ticker MDGL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 17,103,400
- Market Cap $5.73B
- Description
- Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III c...